Your new post is loading...
Current Opinion in Immunology
Volume 25, Issue 3, June 2013, Pages 389–395
Dendritic cell-based nanovaccines for cancer immunotherapyLeonie E Paulis1,Subhra Mandal1,Martin Kreutz,Carl G FigdorDepartment of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
http://dx.doi.org/10.1016/j.coi.2013.03.001, How to Cite or Link Using DOI
Via Alfredo Corell, Anthony M Crasto DR.
Cancer immunotherapy critically relies on the efficient presentation of tumor antigens to T-cells to elicit a potent anti-tumor immune response aimed at life-long protection against cancer recurrence. Recent advances in the nanovaccine field have now resulted in formulations that trigger strong anti-tumor responses. Nanovaccines are assemblies that are able to present tumor antigens and appropriate immune-stimulatory signals either directly to T-cells or indirectly via antigen-presenting dendritic cells. This review focuses on important aspects of nanovaccine design for dendritic cells, including the synergistic and cytosolic delivery of immunogenic compounds, as well as their passive and active targeting to dendritic cells. In addition, nanoparticles for direct T-cell activation are discussed, addressing features necessary to effectively mimic dendritic cell/T-cell interactions.